Alliance Global analyst James Molloy initiated coverage of NanoViricides (NNVC) with a Buy rating and $6 price target NanoViricides is a nano-pharmaceutical company that specializes in creating novel treatments for viral infections, the analyst tells investors in a research note. The firm believes the opportunity for the company “could be significant” should NV-387 show positive data in the planned Phase 2 trials.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNVC:
- NanoViricides files to sell 7.14 shares of common stock for holders
- NanoViricides signs Master Services Agreement with Only Orphans Cote
- NanoViricides Holds 2025 Annual Stockholders Meeting
- NanoViricides reports Q3 EPS (10c) vs. (23c) last year
- NanoViricides Secures $6 Million Through Securities Offering